Susquehanna International Group 13F: Adds $2.6M to ABSI Stake

Susquehanna International Group has significantly boosted its stake in Absci Corporation (NasdaqGS: ABSI), adding 223,967 shares to its portfolio. This increase represents a 52.8% rise in its holdings, bringing the total to 647,878 shares valued at approximately $6.87 million, according to the latest Form 13F filing with the SEC for the reporting period ending May 15, 2026.

What Changed in Susquehanna International Group's Absci Position

Susquehanna International Group increased its investment in Absci Corporation by 223,967 shares, marking a 52.8% increase from its previous holding of 423,911 shares. The total value of Susquehanna's position in Absci now stands at about $6.87 million.

Other Institutional Activity in Absci Corporation

Several other institutional investors have also adjusted their positions in Absci. FMR LLC grew its holdings by 168,995 shares, ending with 22,550,997 shares worth about $67.65 million. ARK Investment Management LLC added 1,175,370 shares, increasing its stake by 9.4% to 13,726,169 shares valued at $41.18 million. Conversely, BlackRock, Inc. slightly reduced its position by 78,238 shares, holding 11,255,194 shares valued at $33.77 million. State Street Corp significantly increased its stake by 1,333,981 shares, marking a 22.3% rise to 7,324,858 shares worth $21.97 million. Vanguard Capital Management LLC opened a new position with 5,886,640 shares, valued at $17.66 million.

Absci Corporation Stock Up 18.5%

Shares of Absci Corporation traded near $10.60 on Friday. The company has a market cap of approximately $1.73 billion. Absci's forward P/E ratio is not meaningful as the company is not currently profitable. The stock has a 52-week low of $2.24 and a high of $11.25. Its 50-day moving average is $5.76, and the 200-day moving average is $3.84. Absci maintains a strong financial position with a current ratio of 6.59 and a quick ratio of 6.28, but it has a debt-to-equity ratio of 2.57.

Recent Earnings

Absci Corporation reported revenue of $1.84 million, though it experienced a revenue decline of 81.8%. The company is not currently profitable, with a return on equity of -63.9%. Absci's next earnings report is expected on August 14, 2026.

Insider Buying and Selling at Absci Corporation

On June 4, 2026, several insiders bought shares of Absci Corporation. Mary Szela purchased a total of 81,400 shares, while Karen McGinnis acquired 49,900 shares. Menelas Pangalos also bought 39,800 shares. These transactions were not part of any pre-planned trading program.

Analysts Set New Price Targets

Analysts remain optimistic about Absci Corporation. On June 25, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $16 price target. Needham reiterated its 'buy' rating on June 24, 2026, with an $11 target. BTIG also maintained a 'buy' rating with a $13 target on the same day. Overall, the consensus among 10 analysts is a 'strong buy', with a mean price target of $12.40.

About Absci Corporation

Absci Corporation is a biopharmaceutical company based in Vancouver, Washington. It focuses on developing antibody therapeutics, with several programs in various stages of clinical trials. These include treatments for inflammatory bowel disease, androgenic alopecia, and oncology. The company collaborates with organizations such as PrecisionLife and Memorial Sloan Kettering Cancer Center to advance its research and development efforts. Absci was founded in 2011 and employs around 140 people under the leadership of CEO Sean McClain.

Bottom Line

Susquehanna International Group's increased stake in Absci Corporation reflects a strong interest in the biotech firm, though it's based on past filings and may not indicate current positions. Absci's stock is drawing attention from both institutional investors and analysts, with a 'strong buy' consensus pointing to potential growth. Investors will be keenly watching the upcoming earnings report in August for further insights.